Synlogic, Inc. filings document the company's corporate-status disclosures, Nasdaq delisting matters, and continuing Exchange Act reporting obligations. Recent Form 8-K and amended Form 8-K reports cover Nasdaq listing-rule notices, the company's public-shell status assessment, common-stock trading suspension and delisting disclosures, and OTC Markets quotation matters tied to the exchange transition.
Proxy and annual meeting materials cover board elections, stockholder voting results, executive compensation, director compensation, equity incentive plans, and related governance matters. The filing record also documents security-holder approval of the 2025 Equity Incentive Plan and material event reporting under Form 8-K.
Synlogic, Inc. filed an amended shelf registration statement on Form S-3/A (ticker SYBX) containing an exhibit index listing charter amendments, bylaws, stock certificate form, indentures, warrant/unit/rights forms, legal opinions, auditor consents, a trustee eligibility statement and a filing fee table. Several certificates of amendment are dated June 15, 2023 and September 27, 2023. The filing shows signatures by company officers and directors dated August 15, 2025.
Synlogic, Inc. (SYBX) filed a shelf registration on Form S-3 to offer up to $150,000,000 of securities, including common stock, preferred stock, debt and warrants. The company reported that it discontinued Synpheny-3, the pivotal Phase 3 study of its lead candidate labafenogene marselecobac (SYNB1934), in February 2024 after an internal review indicated the trial was unlikely to meet its primary endpoint, and stated the decision was not based on safety or tolerability concerns.
Management says its strategy now prioritizes strategic alternatives to enhance stockholder value, including a potential merger or sale, while earlier-stage programs remain in development, notably SYNB1353 which achieved proof of mechanism in a Phase 1 study. The prospectus notes the common stock trades on Nasdaq under SYBX, with 11,698,919 shares outstanding as of August 6, 2025 and a last reported sale price of $1.39 on August 7, 2025.